Daily infusion of dornase alfa

Phase 2Protein / enzyme

FFondation Ophtalmologique Adolphe de Rothschild

Daily infusion of dornase alfa is one of 50 small molecule programs targeting Subarachnoid Hemorrhage. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Subarachnoid HemorrhageActive, not recruiting

Subarachnoid HemorrhagePhase 2

Active, not recruiting

Competition

Competitive Landscape

100 competitors in Subarachnoid Hemorrhage

#DrugCompanyPhaseTrials

Activase

Avlosulfon

1 3

Decadron

AAspen Global Incorporated

Phase 3

1 4

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 6

Ketalar

Boehringer Ingelheim

Phase 3

1 7

Desferal

Alnylam Pharmaceuticals

Phase 2

2 8

Primacor

Sanofi

Phase 2

1 9

Diamox

Teva

Phase 2

1 10

Dynastat

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Subarachnoid Hemorrhage

NCT06723717

Clinical

Trials by Indication[1]

Subarachnoid Hemorrhage1 trial

Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months

Not yet recruiting·FFondation Ophtalmologique Adolphe de Rothschild·Phase 2·NCT06723717·304 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Daily infusion of dornase alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daily infusion of dornase alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daily infusion of dornase alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondation Ophtalmologique Adolphe de Rothschild company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: FFondation Ophtalmologique Adolphe de Rothschild

Daily infusion of dornase alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Subarachnoid Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News